Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 15

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Incidence of Idiosyncratic Drug-Induced Liver Injury Caused by Prescription Drugs

Chen, Vincent L., Rockey, Don C., Bjornsson, Einar S., Barnhart, Huiman, Hoofnagle, Jay H., for the Drug-Induced Liver Injury Network Investigators · 2025 · Drug Safety

Abstract

The incidence of drug-induced liver injury (DILI) is not known for most prescription medications. We aimed to estimate the incidence of DILI for commonly prescribed outpatient drugs. To establish a baseline estimate of DILI incidence, we used the estimated incidence (EI) of amoxicillin/clavulanate DILI from a previous population-based study in Iceland. This was combined with the multicenter prospective DILI Network (DILIN) cohort and the US population-based Medical Expenditure Panel Survey (MEPS). From 2005 to 2019, prescription drugs with at least five bona fide DILIN cases and data from at least 10 of the 15 years from MEPS during that timeframe were included. The EI for ‘drug A’ was calculated as follows: EI(drug A)=EIAC×#DILIN cases of drug A#annual new prescriptions of drug A×#annual new prescriptions of AC#DILIN cases of AC\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\text{EI}(\text{drug A})=\text{EI}\left(\text{AC}\right)\times \frac{\# \; \text{DILIN cases of drug A}}{\# \; \text{annual new prescriptions of drug A}}\times \frac{\# \; \text{annual new prescriptions of AC}}{\# \; \text{DILIN cases of AC}}$$\end{document} In total, 30 drugs met the inclusion criteria, of which 11 were antibiotics, 4 were antiepileptic drugs (AEDs), 4 were statins, and 11 were other drug types. The highest EI was seen with azathioprine and older AEDs, with one DILI case per 349–2329 new prescriptions. The EI of antibiotics ranged greatly, with the highest risk seen for minocycline, amoxicillin/clavulanate, and nitrofurantoin (approximately 1:1000–2400 new prescriptions), and lowest risk for clindamycin, doxycycline, azithromycin, and amoxicillin (approximately 1:40,000–170,000 new prescriptions). The EI for commonly prescribed statins was approximately 1:10,000–50,000. Important medication classes with > 5 million new prescriptions from 2005 to 2019 but fewer than five DILIN cases included β-blockers, thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, selective serotonin reuptake inhibitors, and metformin, which presumably have very low DILI incidence. The highest EI was found for azathioprine, older antiepileptics, and minocycline. In contrast, many widely used drugs are rare causes of DILI. These findings may help clinicians better weigh potential benefits of medications against hepatotoxicity risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40264-024-01486-6

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 18

  1. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5. · DOI · Paper page
  2. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24(8):1187–95. · DOI · Paper page
  3. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004;58(1):71–80. · DOI · Paper page
  4. Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol. 2012;107(9):1380–7. · DOI · Paper page
  5. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10. · DOI · Paper page
  6. Wei G, Bergquist A, Broome U, Lindgren S, Wallerstedt S, Almer S, et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med. 2007;262(3):393–401. · DOI · Paper page
  7. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–52. · DOI · Paper page
  8. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-induced liver injury network (DILIN) prospective study. Drug Saf. 2009;32(1):55–68. · DOI · Paper page
  9. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51(6):2117–26. · DOI · Paper page
  10. Zuvekas SH, Kashihara D. The impacts of the COVID-19 pandemic on the medical expenditure panel survey. Am J Public Health. 2021;111(12):2157–66. · DOI
  11. Suzuki A, Tillmann H, Williams J, Hauser RG, Frund J, Suzuki M, et al. Assessment of the frequency, phenotypes, and outcomes of acute liver injury associated with amoxicillin/clavulanate in 1.4 million patients in the veterans health administration. Drug Saf. 2023;46(2):129–43. · DOI
  12. Gu S, Rajendiran G, Forest K, Tran TC, Denny JC, Larson EA, et al. Drug-induced liver injury with commonly used antibiotics in the all of us research program. Clin Pharmacol Ther. 2023;114(2):404–12. · DOI
  13. Torgersen J, Mezochow AK, Newcomb CW, Carbonari DM, Hennessy S, Rentsch CT, et al. Severe acute liver injury after hepatotoxic medication initiation in real-world data. JAMA Intern Med. 2024;184(8):943–52. · DOI
  14. Björnsson ES. Global epidemiology of drug-induced liver injury (DILI). Current Hepatology Reports. 2019;18(3):274–9. · DOI
  15. Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int. 2022;42(9):1999–2014. · DOI · Paper page
  16. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe’er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816–9. · DOI · Paper page
  17. Urban TJ, Nicoletti P, Chalasani N, Serrano J, Stolz A, Daly AK, et al. Minocycline hepatotoxicity: clinical characterization and identification of HLA-B *35:02 as a risk factor. J Hepatol. 2017;67(1):137–44. · DOI · Paper page
  18. Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology. 2017;152(5):1078–89. · DOI · Paper page

Cited by

See all 15

Metadata

Authors
Chen, V. L., Rockey, D. C., Bjornsson, E. S., Barnhart, H., Hoofnagle, J. H., & for the Drug-Induced Liver Injury Network Investigators
Venue
Drug Safety
Published
2024-09-24
Volume
48
Issue
2
Pages
151-160
ISSN
  • 0114-5916
  • 1179-1942
Cited by
15
References
3
Language
en
Licence
Funders
Division of Diabetes, Endocrinology, and Metabolic Diseases (U01DK065184)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incidence of Idiosyncratic Drug-Induced Liver Injury Caused by Prescription Drugs. https://app.cochat.ai/papers/10.1007/s40264-024-01486-6
The paper
Chen, V. L., Rockey, D. C., Bjornsson, E. S., Barnhart, H., Hoofnagle, J. H., & for the Drug-Induced Liver Injury Network Investigators. (2025). Incidence of Idiosyncratic Drug-Induced Liver Injury Caused by Prescription Drugs. Drug Safety. https://doi.org/10.1007/s40264-024-01486-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.